18-MC (18-methoxycoronaridine)
GPTKB entity
Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
iboga alkaloid |
| gptkbp:CASNumber |
123431-31-8
|
| gptkbp:chemicalFormula |
C22H28N2O3
|
| gptkbp:compatibleWith |
hallucinogenic effects
|
| gptkbp:developedBy |
anti-addiction agent
|
| gptkbp:discoveredBy |
Stanley D. Glick
|
| https://www.w3.org/2000/01/rdf-schema#label |
18-MC (18-methoxycoronaridine)
|
| gptkbp:IUPACName |
(1R,15R,17S,18S)-18-methoxycoronaridine
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
alpha3beta4 nicotinic acetylcholine receptor antagonist
|
| gptkbp:molecularWeight |
368.47 g/mol
|
| gptkbp:PubChem_CID |
3083546
|
| gptkbp:relatedTo |
gptkb:ibogaine
|
| gptkbp:routeOfAdministration |
oral
intraperitoneal |
| gptkbp:studiedBy |
treatment of alcohol addiction
treatment of cocaine addiction treatment of opioid addiction |
| gptkbp:synonym |
18-methoxycoronaridine
|
| gptkbp:UNII |
6QK1E1UO8B
|
| gptkbp:bfsParent |
gptkb:Mind_Medicine
|
| gptkbp:bfsLayer |
7
|